The 2014 Cancer Progress report cites genetics as a key factor in cancer survival rates, causing a flurry of media attention.
Increasingly, patients suffering from cancers such as leukemia are being splintered into smaller groups based on the specific genetics of their malignancies, rather than where the disease occurs.
That has allowed researchers to pinpoint specific genetic mutations with new drugs, such as Spectrum Pharmaceuticals’s Beleodaq for lymphoma, approved by the Food and Drug Administration in July.
View the entire, 112 page report here.
To read a summary, click here.
The Cancer Progress Report website is here.